Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Counterfeiting Task Force To Look At Tighter Wholesaler Licensing

Executive Summary

An FDA task force could look to Florida's new drug wholesaler licensing requirements as a model that all states should adopt to combat counterfeiting

You may also be interested in...



Counterfeiting Bill Would Give FDA Recall Authority, Boost Funding

FDA would receive authority to recall products it believes pose a health risk under a bill introduced by Rep. Steve Israel (D-N.Y.)

Anti-Counterfeiting Interim Step Should Be Paper Pedigree, PhRMA Says

Drug products should contain paper pedigrees as an interim anti-counterfeit measure, the Pharmaceutical Research & Manufacturers of America said at FDA's Oct. 15 Anti-Counterfeit Drug Initiative public meeting in Bethesda, Md

Counterfeiting Bill Would Give FDA Recall Authority, Boost Funding

FDA would receive authority to recall products it believes pose a health risk under a bill introduced by Rep. Steve Israel (D-N.Y.)

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042153

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel